Supernus Pharmaceuticals (SUPN) Receivables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Receivables data on file, last reported at $184.1 million in Q1 2026.

• On a quarterly basis, Receivables rose 26.4% year-over-year to $184.1 million in Q1 2026; TTM through Mar 2026 was $184.1 million, a 26.4% increase from a year earlier, with the FY2025 full-year figure at $189.6 million, up 29.8% from the prior year.
• Receivables for Q1 2026 stood at $184.1 million, down from $189.6 million in the prior quarter.
• Over the last five years, Receivables for SUPN reached as high as $189.6 million in Q4 2025 and fell as low as $136.6 million in Q2 2023.
• Historically, Receivables has averaged $155.6 million across 5 years, with a median of $147.0 million in 2024.
• Across the five-year window, Receivables slipped 13.61% in 2023 and advanced 29.8% in 2025, its largest moves.
• Year by year, Receivables stood at $165.5 million in 2022, then declined by 14.34% to $141.8 million in 2023, then increased by 3.04% to $146.1 million in 2024, then gained by 29.8% to $189.6 million in 2025, then retreated by 2.91% to $184.1 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $184.1 million in Q1 2026, $189.6 million in Q4 2025, and $177.6 million in Q3 2025.